1. Introduction
Chronic kidney disease (CKD) is a progressive disease with significant morbidity and mortality [
1,
2]. Globally, death from CKD rose from the 13
th in 2000 to the 10
th in 2019, and has now reached epidemic proportions, projected to be the fifth leading cause of years of life lost by 2040 [
2]. Given the huge financial and community burden, this imposes developing strategies to halt its progression to kidney failure is imperative. Diagnostic criteria for CKD include a fall in the estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m
2, or albuminuria that persists for at least 3 months [
3,
4,
5]. In its early stage, CKD is largely asymptomatic. This makes its early detection difficult and the initiation of early treatment, which can significantly prevent CKD progression, limited [
4,
5].
Exposure to the environmental pollutant, cadmium (Cd) is inevitable for most people because of its ubiquitous presence in the human diet, evident from a food safety monitoring program, called total diet studies [
6,
7,
8]. Polluted air, active and passive smoking are additional Cd exposure routes [
9,
10,
11]. Cd has no nutritional value or physiological role, and its health impact has long been underappreciated. Concerningly, a tolerable intake of Cd at 25 μg per kg body weight per month, equivalent to 0.83 μg per kg body weight per day (58 µg per day for a 70 kg person), set by the Joint FAO/WHO Expert Committee on Food Additives and Contaminants (JECFA) [
12] is not low enough to be without an appreciable health risk. The JECFA “tolerable” intake level of Cd assumed a nephrotoxicity threshold of Cd excretion at 5.24 μg/g creatinine [
12]. However, it is now known that most of excreted Cd originates from injured or dying tubular cells, and excretion of Cd reflects the injury at the present time, not the risk of injury in the future [
13].
Environmental Cd exposure has been repeatedly linked to CKD in the general population of many countries across the world [
6,
14]. Studies from Japan reported the absorption rates of Cd among women to be as high as 24–45% [
15,
16]. Zinc status and body iron store status are key determinants the body burden of Cd [
17]. Cd accumulates mostly in the kidney tubular epithelium [
18,
19,
20]. Here, it impairs mitochondrial function and promotes the generation of reactive oxygen species (ROS) [
21], disrupts calcium homeostasis by the endoplasmic reticulum with resultant tubular cell death [
22,
23]. Of interest, a recent study has shown that the ferroptosis and injury to kidney tubular cells due to Cd was through its induction of heme oxygenase-1 [
24].
Ample evidence suggests that exposure to low-concentrations of Cd increases the risk of low eGFR [
14]. Reductions in eGFR after Cd exposure are irreversible, and it is likely to decline even further if exposure persists [
25]. The present study aimed to unveil a dose-response relationship and a cause-effect inference of Cd exposure, tubular injury and GFR reduction by multiple-regression and mediation analyses. It aimed also to determine the body burden of Cd at which kidney damage occurs.
Data were from apparently healthy, non-diabetics Thai nationals (n = 737) of which 32.2% and 9.1% had hypertension and low eGFR, respectively. Their excretion of Cd (E
Cd) and N-acetyl-β-D-glucosaminidase (E
NAG), a marker of tubular cell damage, were normalized to creatinine clearance (C
cr), as E
Cd/C
cr and E
NAG/C
cr. This C
cr-normalization corrects for urine dilution and the number of functioning nephrons, and it is not influenced by muscle mass [
26]. For comparisons, E
Cd and E
NAG were also normalized to creatinine excretion (E
cr), as E
Cd/E
cr and E
NAG/E
cr. This Ecr-normalization corrects for urine dilution only, and it is affected by muscle mass which varies widely among people. Previously, E
cr-adjustment was found to introduce a high degree of a statistical uncertainty, leading to non-statistical significance of Cd effects, and underestimation of the severity of kidney damage due to a cumulative burden of Cd [
27,
28].
3. Results
3.1. Study Subjects
Environmental Cd exposure levels and demographic characteristics of study subjects can be found in
Table 1.
The present cohort consisted of 737 persons with mean age of 48.1 (range: 16-87 years) and the overall mean ECd/Ccr of 0.051 µg/L filtrate and mean ECd/Ecr of 3.72 µg/g creatinine. The overall percentages of women and smokers were 60.7% and 42.7% respectively. Hypertension occurred more commonly (32.2%) than low eGFR (9.1%). There were 192 and 545 persons in a low-and high-Cd burden groups, defined as ECd/Ccr below 0.01 and ≥ 0.01 µg/L filtrate, respectively. Smoking was highly prevalent among men in both groups (43.5% vs. 81.8%).
In the low-Cd burden group, men and women were in equal numbers and they had the same mean values for all parameters measured, with an exception of age, where mean age in women was 6.2 years older than men. No male-female differences in mean values for ECd/Ecr, ENAG/Ecr, ECd/Ccr, or ENAG/Ccr.
In the high Cd-burden group, women constituted 62%, but they were of the same age as men (mean age 52.8 for men and 50.4 for women). The mean BMI, mean eGFR and % hypertension all were higher in women than men. However, the mean ECd/Ecr in women was lower, compared to men (4.21 vs 6.01 µg/g creatinine), due most likely to the very high prevalence of smoking in men (81.8% vs 32.3%). Mean values for ENAG/Ecr, ECd/Ccr and ENAG/Ccr in men and women of this high-Cd burden group were similar.
3.2. Moderate-to-Strong Association of ENAG/Ccr with ECd/Ccr
Results of the multiple linear regression of the tubular injury, E
NAG/C
cr can be found in
Table 2.
Age, BMI, eGFR and smoking appeared to have differential influences on E
NAG/C
cr that depended on gender and a body burden level of Cd (
Table 3). In comparison, E
Cd/C
cr and hypertension were consistently associated with E
NAG/C
cr across four subgroups.
ENAG/Ccr varied directly with ECd/Ccr in men (β = 0.447), women (β = 0.394), the low-Cd burden (β = 0.287), and the high-Cd burden groups (β = 0.145). Similarly, a positive association between ENAG/Ccr and hypertension was observed in men (β = 0.167), women (β = 0.169), the low-Cd burden (β = 0.180), and the high-Cd burden groups (β = 0.158).
E
NAG/C
cr varied directly with BMI in only women (β =0.132), while showing an inverse association with age in women (β = −0.170) and the high-Cd burden group (β = −0.124). An inverse association of E
NAG/C
cr and eGFR was found also in women (β =−0.178) and the high-Cd burden group (β = −0.223). In comparison, an inverse association of E
NAG/E
cr and eGFR was statistically insignificant in men, women and the low-Cd burden group (
Table S1).
3.3.Qunatification of Effects of Cadmium and Tubular Injury on eGFR
Results of logistic regression of the low eGFR are provided in
Table 3.
The prevalence odds ratio (POR) for low eGFR was little affected by gender, hypertension, and smoking, while age, BMI, ECd/Ccr and ENAG/Ccr quartile 4 level were associated with increases in risk of having low eGFR. Per each year increase in age, and per one kg/m2 increase in BMI, POR for low eGFR rose 16.7% (p = 0.001) and 10.9% (p = 0.037), respectively. The POR for low eGFR increased 2.71-fold per doubling ECd/Ccr (p <0.001) and 4.80-fold when ENAG/Ccr rose from quartile 1 to quartile 4 (p = 0.015).
Results of a univariate analysis of eGFR can be found in
Table 4.
More than half (63.3%) of male eGFR variation was accounted for (
Table 4). Age contributed the largest fraction (34%), followed by E
Cd/C
cr (8.1%) and hypertension (1.6%). In women. 44% of their eGFR variation were accounted for. Age, E
Cd/C
cr, and E
NAG/C
cr respectively, contributed 24.9%,11.4% and 3.4% of the variation.
In the low-Cd burden group, 49.4% of the total eGFR variation was accounted for. Age contributed the most to the eGFR variability (38%), followed by smoking × hypertension × ENAG/Ccr interactions (5.9%) and gender (5.1%). ECd/Ccr contributed to only 0.034% of eGFR variation (p = 0.828).
In the high-Cd burden group, seven independent variables together accounted for a nearly half of the total variation in eGFR (49.3%) with no interaction complications. Age contributed the most to the eGFR variability (30%) followed by ECd/Ccr (15%) and ENAG/Ccr quartiles (1.3%).
3.4. Mediation Analysis
The scatterplots of the variables in mediation analysis for the low-Cd burden group are provided in
Figure 1.
A linear dose-response relationship was evident for log[(E
NAG/C
cr) × 10
3) vs log [(E
Cd/C
cr) × 10
5] (
Figure 1a), eGFR vs log [(E
Cd/C
cr) × 10
5] (
Figure 1b) in both men and women. For the eGFR vs log[(E
NAG/C
cr) × 10
3), a dose-response relationship was present only in men (
Figure 1c).
Results of mediation analysis model for the low-Cd burden group are provided in
Figure 2.
In a simple mediation analysis model (
Figure 2a), there was a significant effect of E
Cd/C
cr on eGFR (β = −0.374,
p <0.001). However, none of its effect was mediated through E
NAG/C
cr, suggested by a nonstatistical significance figure of
a*b (
p = 0.258) (
Figure 2b).
The scatterplots of the variables in mediation for the high-Cd burden group are provided in
Figure 3.
A linear dose-response relationship was evident for log[(E
NAG/C
cr) × 103) vs log [(E
Cd/C
cr) × 10
5] (
Figure 3a), eGFR vs log [(E
Cd/C
cr) × 10
5] (
Figure 3b) and eGFR vs log[(E
NAG/C
cr) × 10
3) (
Figure 1c) in both men and women.
Results of mediation analysis model for the high-Cd burden group are provided in
Figure 4.
In a simple mediation model (
Figure 4a), there was a significant effect of E
Cd/C
cr on eGFR (β = −0.482,
p <0.001). However, none of its effect was mediated through E
NAG/C
cr as the Sobet test informed a nonstatistical significance figure of
a*b (
p = 0.139) by (
Figure 4b).
4. Discussion
In following JECFA’s tolerable intake level of Cd in the human diet [
13], most studies relied on a rise of β
2-microglobulin (β
2M) excretion above 300 µg/g creatinine, as a nephrotoxicity endpoint. However, Cd-induced tubular injury, assessed with an increased NAG excretion, has also been observed, especially in environmental low-dose exposure scenarios. For example, in a study from United Kingdom, E
Cd/E
cr of 0.5 μg/g creatinine was associated with 2.6- and 3.6-fold increases in the likelihood of having abnormal NAG excretion (E
NAG/E
cr > 2 U/g creatinine), compared to an E
Cd/E
cr of 0.3 and < 0.5 μg/g creatinine, respectively [
39]. Hence, a significant increase in risk of having kidney damage has been linked to an E
Cd/E
cr as low as 0.5 μg/g creatinine. This E
Cd/E
cr was one tenth of the current threshold at 5.24 μg/g creatinine. In theory, the most sensitive endpoint should be used as a basis from which exposure limits are determined [
40].
At least 30 publications have shown a dose-response relationship of E
NAG/E
cr and E
Cd/E
cr [
41] Like urine Cd, urine NAG emanates from injured or dying tubular cells [
13,
42,
43]. Therefore, an excreted amount of NAG is proportional to the number of surviving nephrons, and E
NAG and E
Cd can be expected to be closely correlated as shown previously [
13]. For these reasons, the present study focused on E
NAG together with eGFR, which is employed in clinical trials to evaluate the effects of CKD treatment [
3,
4,
5].
E
Cd and E
NAG are most logically normalized to a function of intact nephron mass because they both are released by tubular cells [
6]. GFR is the measurable analog of nephron number; if C
cr is accepted as a surrogate for GFR, C
cr-normalization corrects for differences in nephron mass. C
cr-normalization may overstate the toxicity implied by a robust E
Cd when nephron number is normal, and understate the toxicity implied by a modest E
Cd when nephron number is reduced. The impact of E
cr-normalization of E
Cd and E
NAG are illustrated in SM (Fig. S4 vs Fig. S3).
By multiple regression analysis (
Table 2), E
NAG/C
cr was strongly associated with E
Cd/C
cr in men (β = 0.447) and women (β = 0.394). A linear-dose response relationship in every subgroup was indicated clearly by scatterplots (
Figure 1a and Figure 3a). Similarly, an inverse association of eGFR and E
Cd/C
cr was consistent across subgroups (
Figure 1b and Figure 3b). Notably, however, E
NAG/C
cr was inversely associated with eGFR in women (β = −0.178) and the high-Cd burden group (β = −0.223), not in men or the low Cd-burden group (
Table 2). These discrepancies could be interpreted to suggest that Cd-induced reduction in eGFR and Cd-induced tubular injury, which caused NAG release were independent or unrelated.
Results of mediation models lend support to the above interpretation; a significant effect of E
Cd/C
cr on eGFR was suggested for both the low -(β = −0.374) and high-Cd burden groups (β = −0.482) (
Figure 2a and Figure 4a), while the Sobel test results informed a nonstatistical significance figures of a mediation effect (
a*b) in both groups (
Figure 2b and Figure 4b). Therefore, Cd-induced injury that causes release of NAG appeared to play little or no role in the nephron destruction that reduces GFR. The molecular basis of Cd induced nephron destruction was not apparent from the present study.
As data in
Table 3 and
Table 4 indicate, the risk of having low eGFR was influenced by age, BMI, a level of body burden of Cd, and the severity of tubular injury. A high-Cd body burden and tubular injury contributed, respectively to 15% (
p <0.00) and 1.3% (
p = 0.085) of the variation in eGFR among those who had E
Cd/C
cr ≥ 0.01 µg/L filtrate. In comparison, gender and a low-Cd body burden contributed, respectively to 5.1% (
p = 0.007) and 0.034% (
p = 0.828) in the eGFR variation among subjects who had E
Cd/C
cr < 0.01 µg/L filtrate. These finding suggested that Cd exposure level producing E
Cd/C
cr below 0.01 µg/L filtrate was the least likely to induce a significant damage to kidneys. This low body burden of Cd corresponds to E
Cd/E
cr of 0.01-0.02 µg/g creatinine.
E
Cd/C
cr of less than 0.01 µg/L filtrate, is in ranges with the benchmark dose limit (BMDL) of Cd body burden [
28]. At present, BMDL is a replacement of the no-observed-adverse effect level (NOAEL) due to its shortcoming. NOAEL is referred to as the highest experimental dose level for which the response does not significantly differ from the response in the control group [
41].
An increased risk of low eGFR can now be attributable to environmental Cd exposure [
20]. The BMD values estimated from E
NAG/E
cr and eGFR endpoints using data from 790 Swedish women, aged 53–64 years, were 0.5–0.8 and 0.7–1.2 μg/g creatinine, respectively [
45]. However, in the China Health and Nutrition Survey (n = 8429), of which 641 (7.6%) of participants had CKD, dietary Cd exposure of 23.2, 29.6 and 36.9 μg/day were associated with 1.73-, 2.93- and 4.05-fold increases in the likelihood of having CKD, compared to a dietary exposure of 16.7 μg/day [
44]. An inferred “safe” dietary Cd exposure level would be below 16.7 µg/day.
It seems illogical to base a designation of tolerable Cd intake on ECd, given its origin and the cause of its release are now known. Minimization of Cd exposure is always imperative, but there is no theoretical or empiric basis for delaying that intervention until ECd has reached a predetermined level, and no evidence that reduction of exposure reverses existing injury. Avoidance of foods containing high Cd concentrations, and minimization of exposure make the most sense when ECd/Ccr first suggests active tubular injury.